Literature DB >> 24422119

Early treatment with Herceptin could benefit a wider group of women with breast cancer.

.   

Abstract

Entities:  

Year:  2013        PMID： 24422119      PMCID： PMC3817971          DOI： 10.1038/bonekey.2013.137

Source DB:  PubMed          Journal:  Bonekey Rep        ISSN： 2047-6396


× No keyword cloud information.
  1 in total

1.  HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.

Authors:  Suthinee Ithimakin; Kathleen C Day; Fayaz Malik; Qin Zen; Scott J Dawsey; Tom F Bersano-Begey; Ahmed A Quraishi; Kathleen Woods Ignatoski; Stephanie Daignault; April Davis; Christopher L Hall; Nallasivam Palanisamy; Amber N Heath; Nader Tawakkol; Tahra K Luther; Shawn G Clouthier; Whitney A Chadwick; Mark L Day; Celina G Kleer; Dafydd G Thomas; Daniel F Hayes; Hasan Korkaya; Max S Wicha
Journal:  Cancer Res       Date:  2013-02-26       Impact factor: 12.701
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.